Melanoma

- **Uveal Melanoma**
  - IRB#16162 A Phase 1, Open-label, Study Evaluating Single and Repeated Escalating Intravitreal Doses of ICON-1 in Patients with Uveal Melanoma Who are planned to Undergo Enucleation

- **Adjuvant Therapies**
  - Stages 2B, 2C, or 3 resectable
    - IRB#11848 A Phase III Placebo-controlled trial of POL-103A Vaccine in Post-resection Melanoma Patients with High Risk of Recurrence
  - Stages 3 or 4 resectable
    - IRB#15661 A Phase III Randomized Trial Comparing Either High Dose Interferon or Ipilimumab to Pembrolizumab in Patients with High Risk Resected Melanoma
  - Non-Mutation Specific
    - New study coming soon
  - Stages 3 or 4 unresectable
    - IRB#11313 A Phase II Study of Ipilimumab and HF10 for Stage IIIB/C, or IV Unresected or Metastatic Malignant Melanoma

- **Mutation Specific**
  - New study coming soon
  - NRAS Mutation
  - C-Kit Mutation
  - IRB#15298 Randomized Phase III trial of Dabrafenib + Trametinib followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab followed by Dabrafenib + Trametinib at Progression in Patients With BRAFV600 Mutant Melanoma

- **Stages 3 or 4, unresectable**
  - IRB#15661 A Phase III Randomized Trial Comparing Either High Dose Interferon or Ipilimumab to Pembrolizumab in Patients with High Risk Resected Melanoma

Please refer to Phase I studies for more clinical trial opportunities